Indian export block causes global headache

4 March 2020
indianpharmabig

The Indian government has restricted exports of 26 active pharmaceutical ingredients (APIs) and finished pharmaceutical products, raising concerns about access to medicines as the novel coronavirus begins to spread more rapidly outside of China.

The products, which amount to around a tenth of pharmaceutical exports from the country, include the common pain reliever acetaminophen, or paracetamol.

They also include vitamin products, antibiotics such as erythromycin and tinidazole, and the hormone progesterone. Restrictions are also being applied to antivirals, such as the shingles medicine acyclovir.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical